# Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

> **NCT06023758** · PHASE2 · RECRUITING · sponsor: **Peking University** · enrollment: 18 (estimated)

## Conditions studied

- HER2-positive Locally Advanced Resectable Gastric Cancer

## Interventions

- **DRUG:** KN026
- **DRUG:** KN046
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT06023758
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023758, "Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06023758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*